NCT02983279 is a NA clinical trial of Dietary Intervention in Breast Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

What drugs are being tested in NCT02983279?

Interventions in NCT02983279: Dietary Intervention, Counseling, Therapeutic.

What condition does NCT02983279 study?

NCT02983279 studies Breast Carcinoma, Endometrial Carcinoma, Prostate Carcinosarcoma.

Is NCT02983279 still recruiting?

NCT02983279 is currently completed. Last updated 29 April 2025.

Last reviewed 2025-04-29 · How we verify

NCT02983279

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer

Completed NA Last updated 29 April 2025

What this trial tests

NA trial testing Dietary Intervention in Breast Carcinoma in 49 participants. Completed in 29 December 2022.

Timeline

20 September 2016

Primary endpoint
27 October 2021

29 December 2022

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	49
Start date	20 September 2016
Primary completion	27 October 2021
Estimated completion	29 December 2022
Sites	1 location across United States

Drugs / interventions tested

Dietary Intervention
Counseling
Therapeutic

Conditions studied

Breast Carcinoma — all drugs for Breast Carcinoma →
Endometrial Carcinoma — all drugs for Endometrial Carcinoma →
Prostate Carcinosarcoma — all drugs for Prostate Carcinosarcoma →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Who can join

18 and older, any sex, with Breast Carcinoma or Endometrial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is to determine that sort term calorie restriction will affect tumor biology in biopsy proven breast, endometrial or prostate cancers, which will positively impact biomarkers including miR-21, an onco-miR known to impact cancer outcomes.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027
Energy Restriction and Colorectal Cancer: A Call for Additional Research.
Castejón M, Plaza A, Martinez-Romero J, Fernandez-Marcos PJ, et al · · 2020 · cited 41× · PMID 31906264 · DOI 10.3390/nu12010114
Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer.
Montégut L, de Cabo R, Zitvogel L, Kroemer G. · · 2022 · cited 32× · PMID 35997502 · DOI 10.1158/2159-8290.cd-22-0504
Small Non-Coding-RNA in Gynecological Malignancies.
Dwivedi SKD, Rao G, Dey A, Mukherjee P, et al · · 2021 · cited 30× · PMID 33802524 · DOI 10.3390/cancers13051085
Translating Mechanism-Based Strategies to Break the Obesity-Cancer Link: A Narrative Review.
Smith LA, O'Flanagan CH, Bowers LW, Allott EH, et al · · 2018 · cited 20× · PMID 29102513 · DOI 10.1016/j.jand.2017.08.112
Advances in Diet and Physical Activity in Breast Cancer Prevention and Treatment.
Khalifa A, Guijarro A, Nencioni A. · · 2024 · cited 17× · PMID 39064705 · DOI 10.3390/nu16142262
Regulatory Genetic Networks by microRNAs: Exploring Genomic Signatures in Cervical Cancer.
Pérez-Plasencia C, Orbe-Orihuela YC, Méndez-Herrera A, Deas J, et al · · 2025 · PMID 40564176 · DOI 10.3390/biomedicines13061457

Verify or expand the search:

Other trials of Dietary Intervention

Trials testing the same drug.

NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic · NA · recruiting
NCT07091864 — Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma · NA · recruiting
NCT06954584 — Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovari · Phase 3 · recruiting
NCT06900439 — Exploring Glycemic Responses Through Continuous Monitoring in a Healthy Population · NA · completed
NCT06336902 — Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorec · Phase 1 · recruiting

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

NCT07067138 — A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS- · NA · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07338721 — Does Ultrasound Guidance Axillary Incision Improve Sentinel Lymph Node Detection in Breast Cancer? · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University trials

Trials by the same sponsor.

NCT06974981 — Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry · recruiting
NCT03796884 — Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer · Phase 2 · active not recruiting
NCT03712904 — Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma · Phase 2 · terminated
NCT03807492 — Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWeR) · completed
NCT03477864 — Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progres · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02983279 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Last refreshed: 29 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02983279.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing